Eric Bjerkholt Sells 20,454 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) Director Eric Bjerkholt sold 20,454 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $2.60, for a total value of $53,180.40. Following the completion of the sale, the director directly owned 261,679 shares in the company, valued at $680,365.40. This represents a 7.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Cerus Stock Down 1.2%

CERS opened at $2.56 on Friday. Cerus Corporation has a one year low of $1.15 and a one year high of $3.15. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.06 and a current ratio of 1.63. The stock’s fifty day moving average is $2.36 and its 200-day moving average is $2.20. The company has a market capitalization of $512.95 million, a PE ratio of -51.20 and a beta of 1.77.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. The company had revenue of $59.89 million for the quarter, compared to the consensus estimate of $55.68 million. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%. On average, equities analysts predict that Cerus Corporation will post -0.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Cerus

Several institutional investors and hedge funds have recently bought and sold shares of CERS. Vanguard Group Inc. increased its holdings in shares of Cerus by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 10,783,986 shares of the biotechnology company’s stock valued at $17,147,000 after purchasing an additional 62,663 shares during the period. Wasatch Advisors LP grew its position in Cerus by 2.6% during the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company’s stock valued at $12,033,000 after purchasing an additional 213,917 shares in the last quarter. Senvest Management LLC increased its stake in Cerus by 3.8% in the 1st quarter. Senvest Management LLC now owns 4,114,061 shares of the biotechnology company’s stock valued at $7,488,000 after buying an additional 148,812 shares during the period. Millennium Management LLC increased its stake in Cerus by 17.6% in the 3rd quarter. Millennium Management LLC now owns 3,470,062 shares of the biotechnology company’s stock valued at $5,517,000 after buying an additional 519,301 shares during the period. Finally, Ieq Capital LLC lifted its position in Cerus by 1.1% in the 4th quarter. Ieq Capital LLC now owns 2,423,741 shares of the biotechnology company’s stock worth $4,993,000 after buying an additional 25,771 shares in the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Zacks Research raised Cerus from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 30th. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Friday, May 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cerus in a research report on Wednesday, March 25th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Cerus currently has a consensus rating of “Hold” and an average price target of $4.00.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.